REDACTED JA Antibody Therapeutics COVID-19 REGENERON_FOR RELEASE.pdf

This document provides details of a limited sole source justification for a federal contract opportunity with the Department of the Army Materiel Command Contracting Command Picatinny Arsenal. The contract was awarded to an unknown vendor on January 12, 2021 for an unknown amount to support the production of therapeutic antibodies (casirivimab and imdevimab) in response to the Coronavirus 2019 (COVID-19) national emergency. The justification and approval was executed in accordance with FAR 6.305(b) for a sole source award under contract number W15QKN-21-C-0014.